Loading page…

Report overview

The report describes 2024 as a transformative year following the reverse takeover that created the enlarged CRISM Group. The company advanced its ChemoSeed drug-delivery programme toward a UK clinical trial authorisation, signed a development services contract, and received a European patent grant. The Group reported a £607,000 loss for the year, alongside continued research and development and regulatory activity.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 12 June 2025
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

No standards or assurance data is available for this report.

ESG & Materiality

ESG data

Indicators available in this report:

Employees

No materiality data is available for this report.

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services

Annual Report and Consolidated Financial Statements

Report overview

Document

Standards & Assurance

ESG & Materiality

ESG data

Build your research dataset.

Annual Report and Consolidated Financial Statements

Report overview

Document

Standards & Assurance

ESG & Materiality

ESG data

Build your research dataset.